{"id":"W4402561493","doi":"10.1016/j.annonc.2024.08.184","title":"241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Association of Schools and Colleges of Optometry; Chugai Pharmaceutical; Samsung; European Society for Medical Oncology; Astellas Pharma; Eisai; Genentech; Veracyte; Sociedad Española de Oncología Médica; BeiGene; Mylan; Japanese Breast Cancer Society; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; F. Hoffmann-La Roche; Relay Therapeutics; Seagen; Roche; Celgene; Novartis; Amgen; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Palbociclib; Placebo; Oncology; Internal medicine; Breast cancer; Disease; Overall survival; Cancer; Surgery; Metastatic breast cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005042381,0.0003440083,0.0006620839,0.00007557203,0.0001392713,0.00005133951,0.0001745403,0.0001245776,0.00005364984],"category_scores_gemma":[0.00112823,0.0002267357,0.00008761937,0.000163607,0.0006195271,0.0002587381,0.0001800977,0.0003114124,0.000001589882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007769461,"about_ca_system_score_gemma":0.001026116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002105439,"about_ca_topic_score_gemma":0.002196226,"domain_scores_codex":[0.9975679,0.000356045,0.0005353261,0.0007031105,0.0004150998,0.0004225558],"domain_scores_gemma":[0.9959357,0.00241002,0.0003223875,0.000471406,0.000374075,0.0004863748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7308762,0.0003927768,0.2417915,0.0002382481,0.00111846,0.0001282123,0.001465858,0.0000471629,0.0000634207,0.0002504538,0.004626333,0.01900133],"study_design_scores_gemma":[0.08409897,0.002472925,0.902609,0.0006407517,0.0007124688,0.000002875953,0.0002159259,0.00005670385,0.00006531156,0.004348808,0.004458902,0.0003173786],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9552502,0.001776028,0.00001362507,0.0255366,0.000516859,0.001619027,0.01520215,0.00005463149,0.00003086294],"genre_scores_gemma":[0.9951339,0.0006429426,0.0004363064,0.001471461,0.0009241898,0.0003409952,0.0008602802,0.00007210569,0.0001178085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6608174,"threshold_uncertainty_score":0.9246014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.036486052286007,"score_gpt":0.3264524203934785,"score_spread":0.2899663681074716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}